Investigational Drug Information for Apaziquone
✉ Email this page to a colleague
What is the drug development status for Apaziquone?
Apaziquone is an investigational drug.
There have been 9 clinical trials for Apaziquone.
The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2007.
The most common disease conditions in clinical trials are Urinary Bladder Neoplasms and [disabled in preview]. The leading clinical trial sponsors are Spectrum Pharmaceuticals, Inc, Handok Inc., and Handok Pharmaceuticals Co., Ltd.
Summary for Apaziquone
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 856 |
| WIPO Patent Applications | 600 |
| Japanese Patent Applications | 58 |
| Clinical Trial Progress | Phase 3 (2007-08-01) |
| Vendors | 36 |
Recent Clinical Trials for Apaziquone
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT) | Spectrum Pharmaceuticals, Inc | Phase 3 |
| A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT) | Spectrum Pharmaceuticals, Inc | Phase 3 |
| Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) | Allergan | Phase 3 |
Clinical Trial Summary for Apaziquone
Top disease conditions for Apaziquone
Top clinical trial sponsors for Apaziquone
US Patents for Apaziquone
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
